Sign Out
UserName
Profession Email
Profession Email
Patients with primary sclerosing cholangitis (PSC) who received norucholic acid (NCA), with or without ursodeoxycholic acid (UDCA) background therapy, were more likely to achieve histological and biochemical improvements than those receiving placebo, according to the subgroup analysis of the NUC-5 trial presented at EASL 2026.
MIMS is a trusted, accurate and user-friendly medication information platform. Designed to empower both healthcare professionals and general public to support informed healthcare decisions, our leading drug directory provides clear, reliable information on prescription drugs, over-the-counter medications and other medical resources.
Don’t miss out on key updates in healthcare.
Continue with Google
Sign Up With Email
Already a member?
Sign In
